CABA: מחיר למכירות Cabaletta Bio Inc.

Cabaletta Bio, Inc. (CABA) develops innovative medicines for autoimmune pathologies, leveraging a scientific alliance with the University of Pennsylvania. The price-to-sales ratio reflects the issuer's valuation dynamics, with the current mark standing at . AI systems and robotic bioscreening are accelerating business growth, while the high cost of clinical validation combined with CAR-T patents create a robust defensive barrier.
פילוחים אנליטיים של חברת Cabaletta Bio, Inc (CABA)

For Cabaletta Bio, Inc. (CABA), whose valuation is based on CAR-T therapy patents and stringent FDA barriers, the P/S ratio reflects the market value of every dollar of revenue. This chart is calculated as the ratio of market capitalization to annual turnover, allowing the investor to assess the degree of overpayment for the asset and determine the current phase of the biotechnology business capitalization cycle.